Results 71 to 80 of about 125,200 (262)
Antiplatelet agents in perioperative noncardiac surgeries: to maintain or to suspend?
, 2018 Juliana Maria Dantas Mendonça Borges,1,2,* Fernanda Oliveira de Carvalho,1,* Isla Alcântara Gomes,3,* Mario Borges Rosa,4,* Antonio Carlos Sobral Sousa1,* 1Nucleus of Post-Graduation in Health Sciences, Federal University of Sergipe, S ...
Borges JMDM +4 more
core
Republished: Antiplatelet therapy for secondary prevention of coronary artery disease
, 2015 The choice and duration of antiplatelet therapy for secondary prevention of coronary artery disease (CAD) is determined by the clinical context and treatment strategy.
Windecker, Stephan, Pilgrim, Thomas
core +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT A 34‐year‐old man with no cardiovascular history presented with anterior ST‐elevation myocardial infarction and a large thrombotic occlusion of the mid left anterior descending artery. Following potent antithrombotic therapy and mechanical thrombus aspiration, angiography revealed vessel patency without residual significant stenosis, allowing ...
Domenico Simone Castiello +3 more
wiley +1 more source
Protective Effect of Phytic Acid in Cardiovascular Diseases: A Systematic Review
ChemFoodChem, EarlyView.ABSTRACT Cardiovascular diseases (CVDs) are a cluster of ailments that impact the heart and blood vessels and are a primary public health problem of mortality on a global scale. Phytic acid, a dietary constituent frequently present in foods like seeds, has been linked to many pharmacological attributes, including anti‐cancer, antioxidant, anti ...
Marta M. S. de Freitas Almeida +7 more
wiley +1 more source
, 2010 Margaret M Marczewski1, Marek Postula1,2, Dariusz Kosior111st Chair and Department of Cardiology, Central University Hospital, Medical University of Warsaw, Warsaw, Poland; 2Department of Experimental and Clinical Pharmacology, Medical University of ...
Margaret M Marczewski +2 more
core
Clinical Pharmacology &Therapeutics, EarlyView.CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao +8 more
wiley +1 more source
Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
, 2010 Hussam M Tayeb, Adam J Nelson, Scott R Willoughby, Matthew I WorthleyCardiovascular Research Centre, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, AustraliaAbstract: Platelets play a central role ...
Scott R Willoughby +3 more
core
, 2014 We investigated and evaluated the demographics, clinical and laboratory features, treatment responses, and disease duration of 25 children with immune thrombocytopenia (ITP) eligible for detection of antiplatelet antibodies.
Ho, Wan-Ling;Lee, Chin-Cheng;Chen, Chiung-Ju;Lu, Meng-Yao;Hu, Fu-Chang;Jou, Shiann-Tarng;Lin, Dong-Tsamn;Lin, Kai-Hsin +1 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro +15 more
wiley +1 more source
, 2012 Dan J FintelBluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAAbstract: Clinical presentations of atherothrombotic vascular disease, such as acute coronary syndromes, ischemic stroke or transient ...
Fintel DJ
core